



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/993,304         | 11/23/2001          | George Jackowski      | 2132.095               |

CONFIRMATION NO. 5360

## FORMALITIES LETTER



\*OC000000007178008\*

Michael A. Slavin, Esq.  
McHale & Slavin, P.A.  
Suite 402  
4440 PGA Boulevard  
Palm Beach Gardens, FL 33410

Date Mailed: 12/10/2001

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

02/21/2002 EAREGAY1 00000057 501803 09993304

01 FC:201 370.00 CH  
02 FC:202 84.00 CH  
03 FC:203 162.00 CH  
04 FC:205 65.00 CH

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.  
*Applicant must submit \$ 370 to complete the basic filing fee for a small entity.*
- Total additional claim fee(s) for this application is \$246.
  - \$162 for 18 total claims over 20.
  - \$84 for 2 independent claims over 3 .
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 681.**
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance with these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION: : IG HEAVY CHAIN, IG KAPPA, IG LAMBDA  
BIOPOLYMER MARKERS PREDICTIVE  
OF ALZHEIMERS DISEASE

SERIAL NUMBER : 09/993,304

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1743

ATTORNEY DOCKET NO. : 2132.095

RESPONSE TO NOTICE TO FILE MISSING PARTS

CERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on

2/8/2002  
*Kris H. Carden*

Box Sequence  
U.S. Patent & Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Sir:

In the above-identified application, Applicants have received a Notice To File Missing Parts Of Application (Filing Date Granted) form PTO-1533, mailed December 10, 2001, indicating that the oath filed with the above-identified application on November 23, 2001 did not include the signature of the inventors and the application lacks the filing fee. Applicants hereby submit the Declaration for the above-identified application signed by the inventors with the appropriate filing fee. Authorization is given to charge Applicant's Deposit Account No. 50-1803 totaling the amount of \$616.00 (\$370.00 for the filing fee, \$162.00 for 18 extra claims over twenty, and \$84.00 for two extra independent claim). Applicants also authorizes the Applicant's Deposit Account No. 50-1803

for the surcharge of \$65.00 required under 37 C.F.R. §1.16(e) and any additional fees required under 37 C.F.R. §1.15 and §1.17 for the filing of this response.

Applicant also submits herewith a copy of the Notice To File Missing Parts mailed December 10, 2001.

IN THE SPECIFICATION:

Prior to the Claims, please add the following sequence listing:

SEQUENCE LISTING

<110> Jackowski, George

<120> IG Heavy Chain, IG Kappa, IG Lambda Biiopolymer Markers  
Predictive of Alzheimers Disease

<130> 2132.095

<140> 09/993,304

<141> 2001-11-23

<160> 7

<170> PatentIn version 3.1

<210> 1

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> MISC\_FEATURE

<222> (1)..(18)

<223> X is a variable whose identity has not been particularly determined. Via software convention, X may represent Q or K, however such determination is not a requirement for the instantly claimed sequence.

<400> 1

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Ser | Val | Leu | Thr | Gln | Pro | Pro | Ser | Val | Ser | Gly | Ala | Pro | Gly | Gln |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

Arg Val

<210> 2

<211> 17

<212> PRT

<213> Homo sapiens

<400> 2

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Tyr | Ala | Ala | Ser | Ser | Tyr | Leu | Ser | Leu | Thr | Pro | Glu | Gln | Trp | Lys |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

Ser

<210> 3

<211> 18

<212> PRT

<213> Homo sapiens

<400> 3

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Gly | Thr | Ala | Ser | Val | Val | Cys | Leu | Leu | Asn | Asn | Phe | Tyr | Pro |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

Arg Glu

<210> 4

<211> 18

<212> PRT

<213> Homo sapiens

<400> 4

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Gly | Leu | Glu | Trp | Val | Ala | Gly | Leu | Ser | Trp | Asn | Ser | Asp | Asn | Ile |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

Arg Tyr

<210> 5

<211> 21

<212> PRT

<213> Homo sapiens

<400> 5

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Thr | His | Ser | Gly | Glu | Lys | Tyr | Val | Cys | Arg | Glu | Cys | Arg | Arg | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |
|-----|-----|-----|-----|-----|
| Phe | Ser | Gln | Lys | Ser |
|     |     |     | 20  |     |

<210> 6

<211> 15

<212> PRT

<213> Homo sapiens

<400> 6

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | His | Ile | Ala | Leu | Ser | Pro | Arg | Tyr | Leu | Asn | Arg | Lys | Arg | Thr |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |

<210> 7

<211> 16

<212> PRT

<213> Homo sapiens

<400> 7


|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ala | Gly | Tyr | Arg | Ile | Asp | Ser | Trp | Gly | Gln | Gly | Thr | Leu | Val | Thr |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

Applicants have now complied with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. A separate paper copy and an electronic form of the sequence listing are attached hereto. The information recorded in computer readable form is identical to the written sequence listing, neither of which contain new matter. In response to the Notice to File Missing Parts dated December 10, 2001, Applicants submit the application complies with the requirements under 37 C.F.R. §1.821-1.825.

Having now complied with all of the outstanding filing requirements, Applicants respectfully request that this application be placed upon the files for examination.

Date: 2/8/2002

Respectfully submitted,

  
\_\_\_\_\_  
Ferris H. Lander  
Registration No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575





SECRET

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.

INVENTION: : IG HEAVY CHAIN, IG KAPPA, IG LAMBDA  
BIOPOLYMER MARKERS PREDICTIVE  
OF ALZHEIMERS DISEASE

SERIAL NUMBER : 09/993,304

FILING DATE : November 23, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1743

ATTORNEY DOCKET NO. : 2132.095

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)  
I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service as First Class mail  
in an envelope addressed to Commissioner for  
Patents, Washington, D.C. 20231 on 2/8/2002

*Ferris H. Lander*

Box Sequence  
U.S. Patent & Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Sir:

Please find enclosed for filing:

- ☒ Preliminary Amendment
  - ☒ Response to Notice to File Missing Parts
  - ☒ Signed Declaration
  - ☒ Computer Readable Form Sequence Listing (paper copy-4 sheets)
  - ☒ Computer Readable Form Sequence Listing (diskette).
  - ☒ Copy of Notice to File Missing Parts
  - ☒ Please charge Deposit Account No. 50-1803 in the amount of \$681.00 as indicated in the Response.
  - ☒ Please charge any deficiencies or credit any overpayment to Deposit Account No. 50-1803.
- This Transmittal Letter is submitted in duplicate.

Date: 2/8/2002

Respectfully submitted,

By: *Ferris H. Lander*

Ferris H. Lander  
Registration No. 43,377  
McHale & Slavin, P.A.  
4440 PGA Boulevard, Suite 402  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575